← Organon & overview

Organon & vs Alvotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Organon & Co (OGN)

Q2 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

June 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Latest
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Alvotech (ALVO)

Q3 2026
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

July 2026
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

Latest
▲2▼1

Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution

  • Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.

    This is the first major event of the period and a clear negative price driver.

  • $240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.

    This is the period's key financing update and explains both the cash cushion and the added risk.

  • FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.

    This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.

  • Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.

    These are the period's main growth catalysts, adding new revenue streams and pipeline progress.

© 2026 MarketIVWhy